Monitored Anesthesia Care: Dexmedetomidine-Ketamine Versus Dexmedetomidine- Propofol For Chronic Subdural Hematoma

Sponsor
Zagazig University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04621526
Collaborator
(none)
52
1
2
23.7
2.2

Study Details

Study Description

Brief Summary

Inadequate sedation and analgesia indicated by intraoperative movements are markers of inadequate MAC during burr-hole surgery for chronic subdural hematoma evacuation especially when general anesthesia poses high risk for the patients.

Dexmedetomidine, ketamine, propofol intravenous infusion and other agents was used to provide monitored anesthesia care with variable success if used as solitary agents as each drug has its limited use.

Condition or Disease Intervention/Treatment Phase
  • Drug: dexmedetomidine- ketamine
  • Drug: dexmedetomidine- propofol
Phase 1/Phase 2

Detailed Description

  • Null hypothesis (H0): There are no differences between the effects of dexmedetomidine- ketamine and dexmedetomidine- propofol combination for monitored anesthesia care during burr-hole surgery for chronic subdural hematoma evacuation.

  • Alternative hypothesis (H1): There are differences between the effects of dexmedetomidine- ketamine and dexmedetomidine- propofol combination for monitored anesthesia care during burr-hole surgery for chronic subdural hematoma evacuation.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
52 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Monitored Anesthesia Care: Dexmedetomidine-Ketamine Versus Dexmedetomidine- Propofol Combination During Burr-Hole Surgery For Chronic Subdural Hematoma
Actual Study Start Date :
Nov 10, 2020
Anticipated Primary Completion Date :
Oct 1, 2022
Anticipated Study Completion Date :
Nov 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: dexmedetomidine- ketamine

patients will receive combination of ketamine 1mg/kg and dexmedetomidine 1ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and ketamine 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.

Drug: dexmedetomidine- ketamine
patients will receive combination of ketamine 1mg/kg and dexmedetomidine 0.5ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and ketamine 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
Other Names:
  • precedex- katalar
  • Active Comparator: dexmedetomidine- propofol

    patients will receive combination from 1 mg/kg propofol and dexmedetomidine 0.5ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and propofol 1 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.

    Drug: dexmedetomidine- propofol
    patients will receive combination from 1 mg/kg propofol and dexmedetomidine 0.5ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and propofol 1 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
    Other Names:
  • precedex- diprivan
  • Outcome Measures

    Primary Outcome Measures

    1. The onset time of sedation [with in 30 minutes before start of surgery]

      The onset of sedation will be recorded. It is defined as the time from injection of sedative medications till reaching a target sedation level score 3 by modified Observer's Assessment of Alertness and sedation score (OAA/S).

    Secondary Outcome Measures

    1. The extent of airway obstruction [intraopertive]

      The extent of airway obstruction by (1= patent airway, 2= airway obstruction alleviated by jaw thrust, 3= airway obstruction alleviated by positive mask ventilation)

    2. rescue analgesic (fentanyl) [intraoperative]

      Total number of calling intraoperative rescue analgesic (fentanyl) in both groups will be recorded.

    3. number of participant with complications [intraoperative]

      Intraoperative complications such as hypotension (mean arterial blood pressure decreases by > 20% of basal reading), bradycardia (HR decreases by > 20% of basal reading) and bradypnea (RR less than 10 b/m) or hypoxemia (SpO2 less than 95%

    4. Recovery time [with in one hour postoperative]

      Recovery time: time from discontinuation of infusion drugs till spontaneous eye opening.

    5. The Neurological status of participants [at baseline then within one hour postoperative]

      The Neurological status of participants will be assessed before discharge in the PACU using Markwalder's Neurological Grading scale (MNGs) and recorded: Grade 0: no neurologic deficit Grade I: mild symptoms such as headache; absent or mild neurologic deficits such as reflex asymmetry Grade II: drowsiness or disorientation with variable neurologic deficits such as hemiparesis Grade III: stupor, but appropriate responses to noxious stimuli; severe focal signs such as hemiplegia Grade IV: coma with absence of motor response to painful stimuli; decerebrate or decorticate posturing.

    6. surgeon satisfaction [with in 24 hours after surgery]

      surgeon satisfaction using 7- point Likert-like verbal rating scale by asking about how they evaluate their experience with anesthetic management during surgery?" score will be 6 and 7 if they are satisfied.5=very satisfied, 4=satisfied, 3= neutral, 2= unsatisfied and 1= very unsatisfied.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    50 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Patient acceptance.

    • Both sex.

    • Age (50-80) years old.

    • Patient with Body Mass Index (BMI) (25-30kg/m²).

    • American Society of Anesthesiologist (ASA) II / III

    • patient scheduled to burr-hole surgery for chronic subdural hematoma evacuation under MAC.

    Exclusion Criteria:
    • Patient with difficult airway (mallapati III,IV).

    • Altered mental status (psychiatric and anexity disorder).

    • Post-traumatic stress disorders.

    • History of allergy to study drugs.

    • Patient on sedative or hypnotic medication.

    • Patients with on painkiller.

    • Patients with any degree of heart block.

    • Sever liver, respiratory or renal impairment.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Zagazig University Hospitsals Zagazig Egypt 055

    Sponsors and Collaborators

    • Zagazig University

    Investigators

    • Principal Investigator: Alshaimaa Kamel, M.D, Zagazig University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Alshaimaa Abdel Fattah Kamel, principle investigator, Zagazig University
    ClinicalTrials.gov Identifier:
    NCT04621526
    Other Study ID Numbers:
    • 6434
    First Posted:
    Nov 9, 2020
    Last Update Posted:
    Aug 2, 2022
    Last Verified:
    Aug 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 2, 2022